Stonepine Capital Management »

Phathom Pharmaceuticals shares owned by Stonepine Capital Management

Quarter-by-quarter ownership of Phathom Pharmaceuticals (PHAT) shares owned by Stonepine Capital Management from 13F filings

Historical chart of Stonepine Capital Management investment in Phathom Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Phathom Pharmaceuticals held by Stonepine Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Phathom Pharmaceuticals by Stonepine Capital Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $556k 50k 11.11

More positions owned by Stonepine Capital Management

Spdr Series Trust State Street Spd Put Option (XBI)
Verastem Com New (VSTM)
Adma Biologics (ADMA)
Tenax Therapeutics Com New (TENX)
Evolus (EOLS)
Camp4 Therapeutics Corp (CAMP)
Nektar Therapeutics Com New (NKTR)
Terns Pharmaceuticals Call Option (TERN)
Zevra Therapeutics Com New (ZVRA)
Abeona Therapeutics Com New (ABEO)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Establishment Labs Holdings Ord Call Option (ESTA)
Kazia Therapeutics Sponsored Ads (KZIA)
An2 Therapeutics (ANTX)
Alexandria Real Estate Equities Call Option (ARE)

View all positions for Stonepine Capital Management

Top funds holding Phathom Pharmaceuticals

Frazier Life Sciences Management
Medicxi Ventures Management
Invesco
BlackRock
Millennium Management
Carlyle
Vanguard Capital Management
NEA Management Company
683 Capital Management
Ensign Peak Advisors
Catalys Pacific
Jennifer Ranahan
State Street Corporation
Geode Capital Management
Daniel D. Thurber

View all funds holding Phathom Pharmaceuticals